Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

Completed · Phase 1

Conditions studied: Cancer

In brief

Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining trastuzumab with R115777 may kill more tumor cells.

Key facts

Study ID

NCT00005842

Run by

National Cancer Institute (NCI)

People needed

24

Starts

2000-06-01

Last updated by the study team

2013-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Brooke Army Medical Center — Fort Sam Houston, Texas, United States
• Institute for Drug Development — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.